10,716 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,716 shares of the company’s stock, valued at approximately $286,000.

Several other large investors also recently modified their holdings of CSTL. R Squared Ltd bought a new position in shares of Castle Biosciences during the 4th quarter worth approximately $42,000. Quest Partners LLC raised its stake in Castle Biosciences by 54.4% during the third quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after acquiring an additional 1,522 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Castle Biosciences during the fourth quarter worth $128,000. Point72 DIFC Ltd bought a new position in shares of Castle Biosciences during the third quarter valued at $140,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock valued at $158,000 after purchasing an additional 604 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Stephens reiterated an “overweight” rating and set a $41.00 target price on shares of Castle Biosciences in a research report on Thursday, January 2nd. Robert W. Baird upped their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $40.00.

Castle Biosciences Price Performance

Castle Biosciences stock opened at $20.10 on Friday. The stock has a market cap of $562.94 million, a price-to-earnings ratio of 100.51 and a beta of 0.98. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The business’s 50-day simple moving average is $24.29 and its 200 day simple moving average is $28.07.

Insider Buying and Selling

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,715 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $29.62, for a total transaction of $80,418.30. Following the completion of the sale, the insider now owns 82,047 shares in the company, valued at approximately $2,430,232.14. The trade was a 3.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. Insiders sold a total of 44,204 shares of company stock valued at $1,055,988 over the last ninety days. Insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.